Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
Alaina Boyer(Washington University in St. Louis), Ron Bose(University Hospitals Seidman Cancer Center)
Cited by 47
Related Papers
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
|Nature Genetics|2017|673
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
|Nature|2007|351
Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor
|Molecular and Cellular Biology|2015|91